Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

British Journal of Cancer

Volumn 102, Issue 6, 2010, Pages 981-986

  Hsu, C H ^a   Yang, T S ^b   Hsu, C ^a   Toh, H C ^c   Epstein, R J ^d   Hsiao, L T ^e   Chen, P J ^a   Lin, Z Z ^a   Chao, T Y ^f   Cheng, A L ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b Chang Gung Medical Foundation LinKou Branch   (Taiwan)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE;

ADVANCED CANCER; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER INVASION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS VARICES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; HYPONATREMIA; LIVER CELL CARCINOMA; LIVER METASTASIS; LOWER RESPIRATORY TRACT INFECTION; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; SKIN PIGMENTATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

EID: 84984578313     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605580     Document Type: Article

References (34)

1. American Joint Committee on Cancer (1998) AJCC Staging Manual 5th edn, Lippincott Williams & Wilkins: Philadelphia, PA
2. Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F, for the EUROCARE Working Group (2007) Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol 102: 1661-1670; quiz 1660, 1671
3. Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, Ho WM, Lam KC, Chan AT, Mok TS, Yeo W (2009) New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 27: 446-452
4. Chen LT, Liu TW, Chao Y, Shiah HS, Chang JY, Juang SH, Chen SC, Chuang TR, Chin YH, Whang-Peng J (2005) Alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. Aliment Pharmacol Ther 22: 217-226
5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34
6. Collette S, Bonnetain F, Paoletti X, Doffoel M, Bouché O, Raoul JL, Rougier P, Masskouri F, Bedenne L, Barbare JC (2008) Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol 19: 1117-1126
7. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576
8. Ensign LG, Gehan EA, Kamen DS, Thall PF (1994) An optimal three-stage design for phase II clinical trials. Stat Med 13: 1727-1736
9. Farinati F, Rinaldi M, Gianni S, Naccarato R (2000) How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 89: 2266-2273
10. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G (2005) Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 54: 411-418
11. Hennessy BT, Gauthier AM, Michaud LB, Hortobagyi G, Valero V (2005) Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 16: 1289-1296
12. Hsu C, Shen YC, Cheng CC, Hu FC, Cheng AL (2010) Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. Contemp Clin Trials 31: 55-61
13. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
14. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ, for the Panel of Experts in HCC-Design Clinical Trials (2008a) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698-711
15. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, for the SHARP Investigators Study Group (2008b) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390
16. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799
17. National Cancer Institute (2008) Adult primary liver cancer treatment PDQ summary. Available from: http://www.cancer.gov/cancertopics/pdq/ treatment/adult-primary-liver/healthprofessional/
18. National Comprehensive Cancer Network (2007) Clinical practice guidelines in oncology. Hepatobillary cancers. Version 1. http://www.nccn.org/ professionals/physician-gls/PDF/hepatobillary.pdf
19. Palmer DH, Hussain SA, Johnson PJ (2004) Systemic therapies for hepatocellular carcinoma. Expert Opin Invest Drugs 13: 1555-1568
20. Pang R, Poon RT (2006) Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 242: 151-167
21. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD (2004) Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101: 578-586
22. Roche Products Limited (2009) Xeloda summary of product characteristics. Available from http://emc.medicines.org.uk/medicine/4619
23. Sakamoto J, Kondo Y, Takemiya S, Sakamoto N, Nishisho I, Clinical Study Group of Capecitabine (2004) A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. Anticancer Drugs 15: 137-143
24. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550
25. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown Jr RS, Rafii S, Schwartz JD (2008) II Phase trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocel-lular carcinoma. J Clin Oncol 26: 2992-2998
26. Sun W, Haller DG, Mykulowycz K, Rosen M, Soulen M, Capparo M, Faust T, Giantonia B, Olthoff K (2007) Combination of capecitabine and oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 25(18S): (abstr 4574)
27. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocel-lular carcinoma. J Clin Oncol 27: 843-850
28. Twelves C, Glynne-Jones R, Cassidy J, Schüller J, Goggin T, Roos B, Banken L, Utoh M, Weidekamm E, Reigner B (1999) Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 5: 1696-1702
29. Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX (2009) Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 14: 717-725
30. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835-844
31. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109
32. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M (1998) Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28: 68-77
33. Zhu AX (2006a) Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11: 790-800
34. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K (2006b) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 1898-1903